AMGN · Amgen

The thesis

Amgen is modestly more likely than not to beat the S&P 500 over the next three months. Volume-led growth in Repatha, Evenity, Tezspire, Uplizna and Imdelltra now outruns the biosimilar losses on Prolia and Xgeva. The fourth-quarter report, expected in early February 2027 with the first 2027 outlook, settles it.

The rating is Medium because the growth is measured and current but the shares already price much of it. Amgen's third-quarter release on 3 November 2026 showed total revenue of $10.4 billion, up 8% from a year earlier, with product sales growth "driven by volume growth." Non-GAAP earnings per share rose 14% to $6.45. Amgen guided 2026 total revenue to $38.9–39.7 billion and non-GAAP earnings per share to $22.90–23.70. Benzinga and Zacks reported this as a raised outlook.

The market already prices that print. The shares closed at $467.06 on 12 November 2026, up 13.1% over three months. Analyst targets published from 4 November to 12 November 2026 run from $400 to $530, and Leerink ($464), Canaccord ($440) and Guggenheim ($435) sit below that close. Further gains need the 2027 outlook or late-stage pipeline data to add something new.

Bullish and bearish views on Amgen Inc.

The bull case on Amgen Inc. (AMGN), in brief: growth brands now carry the revenue. The bear case: biosimilars are eroding the bone franchise.

Bull case

• Growth brands now carry the revenue. In the third quarter of 2026, Repatha sales rose 37% to $1,085 million, Evenity 39% to $751 million, Tezspire 43% to $538 million, Uplizna 191% to $451 million and Imdelltra 128% to $406 million. Amgen's 3 November 2026 release attributes each gain to volume.
• Repatha outcomes data keeps building. On 5 November 2026 Amgen reported a large real-world study in which Repatha cut fatal or nonfatal heart attacks by 20% compared with ezetimibe. At the American Heart Association meeting on 9 November 2026, Amgen presented data showing Repatha was a highly cost-effective treatment for high-risk patients.
• Dazodalibep adds an immunology asset. In the Phase 3 OASIZ-301 trial in Sjögren's disease, disease activity scores (ESSDAI) fell 5.6 points at week 48 on the 1,500 mg monthly dose, against 3.8 on placebo (adjusted p<0.001). These figures come from the ACR Convergence 2026 late-breaker that Amgen reported on 11 November 2026.
• Analysts raised targets after the report. UBS and Scotiabank each lifted their targets to $530 on 4 November 2026, Argus raised its target to $515 on 12 November 2026, and Daiwa raised its target to $490 from $430 on 11 November 2026.
• MariTide Phase 3 is fully under way. Amgen's 3 November 2026 release says MARITIME-CV and two sleep apnoea studies have completed enrollment, and a head-to-head study against semaglutide is enrolling. Amgen projects about $2.6 billion of 2026 capital spending, including manufacturing built ahead of a potential launch.

Bear case

• Biosimilars are eroding the bone franchise. In the third quarter of 2026, Prolia sales fell 45% to $632 million and Xgeva 47% to $288 million as multiple biosimilars launched, according to Amgen's 3 November 2026 release.
• Older brands face price pressure. Otezla fell 18% to $481 million in the third quarter of 2026. Enbrel's net price fell 14% under Medicare Part D price setting, according to the same release.
• Cash generation slipped. Third-quarter free cash flow was $3.7 billion, down from $4.2 billion a year earlier, which Amgen attributed to working-capital timing. Debt stood at $54.0 billion on 30 September 2026, against cash of $13.2 billion.
• Valuation calls have started. Freedom Broker cut Amgen to Hold on 6 November 2026 while raising its target to $470. Guggenheim (Neutral, $435) and Leerink (Market Perform, $464) also left their targets below the 12 November 2026 close after the report.
• The largest pipeline readout lies in 2027. On 3 November 2026 Reuters reported that initial Phase 3 MariTide results are not expected until 2027. That leaves the shares without a scheduled pipeline readout through year-end 2026.

Price setup

The shares closed at $467.06 on 12 November 2026, 3.5% below the 52-week intraday high of $483.99 set on 5 November 2026. That high came two sessions after the third-quarter report. Closes have held between $460.28 (5 November 2026) and $468.11 (11 November 2026) since then.

The 50-day moving average is $424.87 and the 200-day moving average is $377.80, both as of 12 November 2026. The last close sits above both. The 52-week closing low was $313.85 on 9 December 2025, so the shares have rerated sharply over the year. On adjusted daily closes, the 3-month gain is 13.1%, measured from $412.80 on 14 August 2026.

The case turns on the range set after the report. Holding near the high through the fourth-quarter report keeps the earnings-driven rerating intact. A slide back toward the 50-day average would mean the market is discounting the 2027 outlook early.

Catalysts ahead

• ~31 December 2026 (est.): FDA action on ABP 206, Amgen's nivolumab biosimilar, expected by the end of 2026. An approval adds an oncology biosimilar to a biosimilar unit whose other products grew in the third quarter of 2026, and partly offsets Prolia and Xgeva erosion.
• ~31 December 2026 (est.): Completion of the second Phase 3 dazodalibep study, OASIZ-303, in Sjögren's disease. Analysts expect two Phase 3 studies to support approval, so this result decides whether dazodalibep moves toward a filing.
• ~3 February 2027 (est.): Fourth-quarter 2026 report and first 2027 outlook. The 2027 revenue and earnings guide shows whether growth brands keep outrunning biosimilar and Medicare price erosion; this is the event that settles the three-month call.
• 2027 (est.): First Phase 3 MariTide obesity results. MariTide data decide whether Amgen gains a share of the obesity drug market; strong or weak data would reprice the shares more than any base-business result.

What would change the view

A daily close below $424, under the 50-day moving average, which would show the post-report rerating unwinding; or a 2027 revenue outlook at the fourth-quarter report below $38.9 billion, the low end of the 2026 range.

The risks this note tracks, each with what would confirm it:

• Biosimilar erosion of Prolia and Xgeva speeds up and overwhelms growth from newer brands in 2027. Confirmed by: a 2027 revenue outlook at the fourth-quarter report that is flat or down from the 2026 range, or combined Prolia and Xgeva fourth-quarter sales falling faster than the third quarter's 45–47% declines.
• Medicare price setting and sales deductions cut net prices on Enbrel and Otezla more than expected. Confirmed by: fourth-quarter 2026 Enbrel or Otezla sales falling further from a year earlier, with management citing net price as the main driver.
• Repatha growth slows as competing cholesterol drugs reach the market. Confirmed by: fourth-quarter 2026 Repatha sales growth well below the 37% rate reported for the third quarter of 2026.
• MariTide timing slips or its profile disappoints relative to Eli Lilly and Novo Nordisk drugs. Confirmed by: Amgen pushing first MARITIME Phase 3 readouts beyond 2027, or competitor data that sets a higher weight-loss or tolerability bar.
• Valuation caps the shares after the November rerating, leaving them flat while the index rises. Confirmed by: more analyst downgrades to Hold or Neutral citing valuation, following Freedom Broker's on 6 November 2026.

What it trades with

Amgen trades as a large-cap biopharma name. It tends to move with broad healthcare funds such as XLV and IBB on drug-pricing and policy headlines. Headlines about obesity drugs from Eli Lilly and Novo Nordisk also move it, through investors' view of MariTide, even though MariTide has no sales yet. Its revenue base runs across cardiovascular, bone, oncology and immunology drugs. That makes it less sensitive than a single-product obesity name to any one trial or pricing deal in that market.